Second, the exome-wide significant series of > 100 SLC30A8 protective missense alleles from the most recent T2D exome sequencing study [65••] could be used to probe the SLC30A8 “dose-response” curve: each allele could be introduced into a molecular or cellular assay (such as zinc transport or insulin secretion), and their effects on these assays could then be compared to their T2D protective effects to calibrate the relationship between T2D risk and the biological process measured by the assay. Here, SLC30A8 is linked to type 2 diabetes mellitus.